Gesellschaftsrecht / M&A

IP / IT

Kapitalmarkt

Steuern

Arbeitsrecht und Vergütung für Führungskräfte

Bioversys-web-640x140

Homburger News

20250129_Bioversys

On January 29, 2025, BioVersys AG, a clinical-stage biopharmaceutical company developing and commercializing novel antibacterial products for life-threatening infections domiciled in Basel, Switzerland, announced the launch of its Initial Public Offering (IPO) on SIX Swiss Exchange, the publication of the offer price and the start of the bookbuilding process. The IPO comprises a primary offering targeting gross proceeds of CHF 80 m (including an over-allotment option targeting gross proceeds of CHF 5 m). The implied market capitalization of the company, assuming all offered shares are sold in the IPO and the over-allotment option is exercised in full, is approximately CHF 212.9 m. The first day of trading is expected to be February 7, 2025.
BioVersys focuses on identifying, developing and commercializing novel antibacterial products for serious life-threatening infections caused by multi-drug resistant (MDR) bacteria. The Company&#8217;s most advanced R&amp;D programs address nosocomial pneumonia and blood stream infections caused by Acinetobacter baumannii (BV100, phase 3-ready) and tuberculosis (alpibectir, phase 2a). In addition to its domicile in the biotech hub in Basel, Switzerland, BioVersys has operations in in Lille, France, Delaware, United States and Guangzhou, China.
Citigroup Global Markets Limited, UBS AG and Stifel Europe AG are acting as Joint Global Coordinators and Joint Bookrunners on the IPO, Mirabaud &amp; Cie SA and Octavian AG as Selling Agents.
Homburger is advising BioVersys on all aspects of the IPO as lead counsel. The Homburger team is co-led by Dieter Gericke and Lorenzo Togni and includes Thierry Burckhardt, Magda Aref, Simone Schmid, Raphael Linder, Harun Cetin and Leander Etter (all Corporate / M&amp;A and Capital Markets). Luca Dal Molin and Kristina Martinovic (both IP / IT) are providing intellectual property advice, Jeremy Reichlin (Employment and Executive Compensation) is providing employment and executive compensation advice, and Reto Heuberger and Philippe Weber (both Tax) are providing tax advice.

Homburger advises BioVersys AG on its IPO on SIX Swiss Exchange

Regulierung

novo-nordisk_web_640x140

Homburger and Novo Nordisk_Novo Holdings_Catalent

On December 18, 2024, Novo Nordisk announced that it has successfully completed its USD 11 bn acquisition of three manufacturing sites from Novo Holdings A/S. The completion follows the finalization of Novo Holdings&#8217; acquisition of Catalent, Inc., a global contract development and manufacturing organization. The three acquired sites are specialized in the sterile filling of drugs and are located in Anagni (Italy), Brussels (Belgium) and Bloomington IN (USA).
Novo Nordisk is a leading global healthcare company headquartered in Denmark. Its purpose is to drive change to defeat serious chronic diseases, built upon its heritage in diabetes.
Catalent is a global contract development and manufacturing organization headquartered in Somerset, New Jersey. The company has over 50 global sites and employs more than 18,000 people.
A Homburger team comprising Andreas Müller, Anna Peter, Simone Schmid, Bianca Nedwed, Florian Bruggisser and Maria Braun (all Corporate / M&amp;A), Allegra Arnold, Meret Horisberger and Harun Cetin (all Regulatory), Jeremy Reichlin (Employment) as well as Reto Heuberger, Juliette Buob and Philipp Stiegeler (all Tax) advised Novo Nordisk on the transaction.

Homburger advises on Novo Nordisk / Novo Holdings / Catalent transaction

Immobilien

Finanzierungen und Anlageprodukte

Pollen_Street_bw_640x140

Homburger and Pollen Street Capital

Pollen Street Capital has acquired Etops Group, further consolidating the European wealthtech market by adding to its existing investments in niiio Finance Group, fundsaccess, MiFID-Recorder, and FundHero. As part of the transaction, key shareholders of Etops Group agreed to reinvest in the wider group.
Pollen Street Capital is a private capital asset manager with more than GBP 4.2 bn in assets under management.
Etops Group is a Swiss-based provider of software solutions and business process outsourcing services in the wealth management sector.
The Homburger team advising Pollen Street Capital comprised Andreas Müller, Olivier Bühlmann, Jonas Stähli and Harun Cetin (all Corporate / M&amp;A, Real Estate), Reto Heuberger and Philippe Weber (both Tax) and Daniel Junginger (Financing and Investment Products).

Harun
Cetin

Homburger advises BioVersys AG on its IPO on SIX Swiss Exchange

Homburger advises on Novo Nordisk / Novo Holdings / Catalent transaction

Homburger advised Pollen Street Capital on its acquisition of Etops Group

Join the Team

Harun Cetin

Karriere

Sprachen

Zulassung

Teams

HarunCetin

Homburger advises BioVersys AG on its IPO on SIX Swiss Exchange

Homburger advises on Novo Nordisk / Novo Holdings / Catalent transaction

Homburger advised Pollen Street Capital on its acquisition of Etops Group

Join the Team

Harun Cetin

Karriere

Sprachen

Zulassung

Teams

Harun
Cetin